These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 12720146

  • 1. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
    Treon SP, Kelliher A, Keele B, Frankel S, Emmanouilides C, Kimby E, Schlossman R, Mitsiades N, Mitsiades C, Preffer F, Anderson KC.
    Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
    [Abstract] [Full Text] [Related]

  • 2. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
    Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC.
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.
    J Immunother; 2001 Oct; 24(3):272-9. PubMed ID: 11394506
    [Abstract] [Full Text] [Related]

  • 5. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 Oct; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
    San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sánchez-Guijo F, Sánchez ML, Escribano L, Bárez A, Moro MJ, Hernández J, Aguilera C, Cuello R, García-Frade J, López R, Portero J, Orfao A.
    Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
    Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P.
    Am J Clin Pathol; 2005 Sep; 124(3):414-20. PubMed ID: 16191510
    [Abstract] [Full Text] [Related]

  • 10. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
    Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP.
    Clin Lymphoma Myeloma; 2006 May 01; 6(6):478-83. PubMed ID: 16796779
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
    Vitolo U, Ferreri AJ, Montoto S.
    Crit Rev Oncol Hematol; 2008 Aug 01; 67(2):172-85. PubMed ID: 18499469
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation.
    Walsh SH, Laurell A, Sundström G, Roos G, Sundström C, Rosenquist R.
    Leuk Res; 2005 Jul 01; 29(7):729-34. PubMed ID: 15927667
    [Abstract] [Full Text] [Related]

  • 18. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
    Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.
    J Immunother (1991); 2001 May 01; 24(3):272-279. PubMed ID: 11395644
    [Abstract] [Full Text] [Related]

  • 19. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.
    Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ.
    Semin Oncol; 2003 Apr 01; 30(2):182-6. PubMed ID: 12720133
    [Abstract] [Full Text] [Related]

  • 20. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
    Treon SP, Anderson KC.
    Semin Oncol; 2000 Dec 01; 27(6 Suppl 12):79-85. PubMed ID: 11226004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.